Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:32 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved outcomes when combined with Keytruda. This is a significant positive catalyst for the company, as it validates the mRNA platform beyond COVID vaccines and opens a large oncology market.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:27 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:22 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:17 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the treatment plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:12 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom mRNA cancer therapy. Patients receiving the treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:07 AM UTC

Segments 13-17 describe Moderna's positive Phase 3 cancer vaccine results, a material positive catalyst that drove a 177% stock increase. This supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 07:02 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive market reaction. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:57 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine in combination with Keytruda, showing improved recurrence-free survival in melanoma patients. The stock surged 177% on the news, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:52 AM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:47 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.